In 2019, Schwartz's group showed that immune checkpoint blockade targeting the PD-1/PD-L1 pathway might have beneficial results in a tau-driven disease model resembling Alzheimer's disease (AD). This evidence concerns the gene PDCD1 and Alzheimer disease.